Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Acquisition of exclusive commercialization rights for European markets
Connecting new production and consumption areas of chilled food by low-carbon transportation services
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated